The nuclear factor E2-related factor 2 and age-related macular degeneration

Arq Bras Oftalmol. 2023 Mar-Apr;86(2):178-187. doi: 10.5935/0004-2749.20230024.

Abstract

After the discovery of anti-vascular endothelial growth factor agents as treatment of wet age-related macular degeneration, the number of studies with the objective to understand the molecular mechanisms involved in the age-re lated macular degeneration genesis has increased. The importance of the nuclear factor e2-related factor 2 lies in its activation-derived proteins being involved in the maintenance of the redox balance and consequent prevention of degenerative macular disease. This article aims to present the characteristics of nuclear factor e2-related factor 2 and describe the main nuclear factor e2-related factor 2-activated antioxidant enzymes that contribute to the preservation of vision.

MeSH terms

  • Angiogenesis Inhibitors* / therapeutic use
  • Humans
  • Intravitreal Injections
  • NF-E2-Related Factor 2 / therapeutic use
  • Ranibizumab / therapeutic use
  • Vision, Ocular
  • Wet Macular Degeneration* / drug therapy

Substances

  • Angiogenesis Inhibitors
  • NF-E2-Related Factor 2
  • Ranibizumab